Publications
-
Cytotoxic T lymphocyte responses against melanocytes and melanoma.
Chang GY,
Kohrt HE, Stuge TB, Schwartz EJ, Weber JS, Lee PP.
J Transl Med.
2011;
9
(1):
122
-
Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients.
Simons DL,
Lee G, Kirkwood JM, Lee PP.
J Transl Med.
2011:
9
52
-
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
Butterfield LH,
Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML.
Clin Cancer Res.
2011;
17
(10):
3064-76
-
T cell state transition produces an emergent change detector.
Kim PS,
Lee PP.
J Theor Biol.
2011;
275
(1):
59-69
-
Quantitative, architectural analysis of immune cell subsets in tumor-draining lymph nodes from breast cancer patients and healthy lymph nodes.
Setiadi AF,
Ray NC, Kohrt HE, Kapelner A, Carcamo-Cavazos V, Levic EB, Yadegarynia S, van der Loos CM, Schwartz EJ, Holmes S, Lee PP.
PLoS One.
2010;
5
(8):
e12420
-
An Interactive Java Statistical Image Segmentation System: GemIdent.
Holmes S,
Kapelner A, Lee PP.
J Stat Softw.
2009;
30
(10)
-
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.
Kohrt H,
Johannsen A, Hoppe R, Horning SJ, Rosenberg SA, Advani R, Lee PP.
Oncol Res.
2009;
18
(5-6):
287-92
-
Impaired interferon signaling is a common immune defect in human cancer.
Critchley-Thorne RJ,
Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP.
Proc Natl Acad Sci U S A.
2009;
106
(22):
9010-5
-
Development and dynamics of robust T-cell responses to CML under imatinib treatment.
Chen CI,
Maecker HT, Lee PP.
Blood.
2008;
111
(11):
5342-9
-
Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules.
Liu X,
Lagenaur LA, Lee PP, Xu Q.
Appl Environ Microbiol.
2008;
74
(15):
4626-35
-
Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models.
Kim PS,
Lee PP, Levy D.
Bull Math Biol.
2008;
70
(3):
728-44
-
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.
Critchley-Thorne RJ,
Yan N, Nacu S, Weber J, Holmes SP, Lee PP.
PLoS Med.
2007;
4
(5):
e176
-
Gene expression network analysis and applications to immunology.
Nacu S,
Critchley-Thorne R, Lee P, Holmes S.
Bioinformatics.
2007;
23
(7):
850-8
-
Modeling regulation mechanisms in the immune system.
Kim PS,
Lee PP, Levy D.
J Theor Biol.
2007;
246
(1):
33-69
-
Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N.
Liu X,
Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, Lee PP, Xu Q.
Antimicrob Agents Chemother.
2006;
50
(10):
3250-9
-
Rational design of combination enzyme therapy for celiac sprue.
Siegel M,
Bethune MT, Gass J, Ehren J, Xia J, Johannsen A, Stuge TB, Gray GM, Lee PP, Khosla C.
Chem Biol.
2006;
13
(6):
649-58
-
Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses.
Kohrt HE,
Shu CT, Stuge TB, Holmes SP, Weber J, Lee PP.
J Immunother.
2005 Jul-Aug;
28
(4):
297-305
-
Agent-based modeling of the context dependency in T cell recognition.
Casal A,
Sumen C, Reddy TE, Alber MS, Lee PP.
J Theor Biol.
2005;
236
(4):
376-91
-
Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray.
Chen DS,
Soen Y, Stuge TB, Lee PP, Weber JS, Brown PO, Davis MM.
PLoS Med.
2005;
2
(10):
e265
-
Memory T cells have gene expression patterns intermediate between naive and effector.
Holmes S,
He M, Xu T, Lee PP.
Proc Natl Acad Sci U S A.
2005;
102
(15):
5519-23
-
Post-transplantation dynamics of the immune response to chronic myelogenous leukemia.
DeConde R,
Kim PS, Levy D, Lee PP.
J Theor Biol.
2005;
236
(1):
39-59
-
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer.
Kohrt HE,
Nouri N, Nowels K, Johnson D, Holmes S, Lee PP.
PLoS Med.
2005;
2
(9):
e284
-
Diversity and recognition efficiency of T cell responses to cancer.
Stuge TB,
Holmes SP, Saharan S, Tuettenberg A, Roederer M, Weber JS, Lee PP.
PLoS Med.
2004;
1
(2):
e28
-
Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors.
Xu T,
Shu CT, Purdom E, Dang D, Ilsley D, Guo Y, Weber J, Holmes SP, Lee PP.
Cancer Res.
2004;
64
(10):
3661-7
-
T-cell responses to cancer.
Lee PP,
Methods Cell Biol.
2004:
75
513-32
-
A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
Pullarkat V,
Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS.
Clin Cancer Res.
2003;
9
(4):
1301-12
-
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
Molldrem JJ,
Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM.
J Clin Invest.
2003;
111
(5):
639-47
-
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells.
Rubio V,
Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP.
Nat Med.
2003;
9
(11):
1377-82
-
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J,
Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP.
Cancer.
2003;
97
(1):
186-200
-
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.
Chang TL,
Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, Schoolnik GK, Ho DD, Hillier SL, Holodniy M, Lewicki JA, Lee PP.
Proc Natl Acad Sci U S A.
2003;
100
(20):
11672-7
-
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.
Keilholz U,
Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB.
J Immunother.
2002 Mar-Apr;
25
(2):
97-138
-
A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.
Chang AE,
Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ.
Clin Cancer Res.
2002;
8
(4):
1021-32
-
Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients.
Falco DA,
Nepomuceno RR, Krams SM, Lee PP, Davis MM, Salvatierra O, Alexander SR, Esquivel CO, Cox KL, Frankel LR, Martinez OM.
Transplantation.
2002;
74
(4):
501-10
-
A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.
Jonuleit H,
Giesecke-Tuettenberg A, Tüting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH.
Int J Cancer.
2001;
93
(2):
243-51
-
Effects of Interleukin-12 on the immune response to a multi-peptide vaccine for resected metastatic melanoma
Lee, PP;,
Wang, F; Kuniyoshi, J; Rubio, V; Stuge, T; Groshen, S; Gee, C; Lau, R; Jeffery, G; Margolin, K; Marty, V; Weber, J.
Journal of Clinical Oncology.
2001
-
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.
Molldrem JJ,
Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM.
Nat Med.
2000;
6
(9):
1018-23
-
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C,
Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD.
J Exp Med.
2000;
192
(11):
1637-44
-
The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.
Hernández J,
Lee PP, Davis MM, Sherman LA.
J Immunol.
2000;
164
(2):
596-602
-
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
Molldrem JJ,
Lee PP, Wang C, Champlin RE, Davis MM.
Cancer Res.
1999;
59
(11):
2675-81
-
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.
Lee PP,
Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM.
Nat Med.
1999;
5
(6):
677-85
-
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C,
Savage PA, Lee PP, Davis MM, Greenberg PD.
J Immunol.
1999;
162
(4):
2227-34
-
T helper 2-dominant antilymphoma immune response is associated with fatal outcome.
Lee PP,
Zeng D, McCaulay AE, Chen YF, Geiler C, Umetsu DT, Chao NJ.
Blood.
1997;
90
(4):
1611-7
-
An oligonucleotide blocks interferon-gamma signal transduction.
Lee PP,
Ramanathan M, Hunt CA, Garovoy MR.
Transplantation.
1996;
62
(9):
1297-301
-
Pharmacokinetics of 111In-labelled monoclonal antibody ZCE-025 and fragments in tumour-bearing mice.
Koziol JA,
Lee PP, Dillman RO, Fagnani R, Halpern SE.
Nucl Med Commun.
1995;
16
(4):
299-305
-
Origin of regional and species differences in intestinal glucose uptake.
Ferraris RP,
Lee PP, Diamond JM.
Am J Physiol.
1989;
257
(5 Pt 1):
G689-97
Help